{"url_path":"/sec/fth/8-k/2026-06-15/item-5-03","section_key":"item-5-03","section_title":"Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1829802/0001193125-26-270330-index.html","accession_number":"0001193125-26-270330","cik":"0001829802","ticker":"FTH","issuer_name":"Faeth Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1829802/0001193125-26-270330-index.html","primary_entity_key":"0001829802","primary_entity_name":"Sensei Biotherapeutics, Inc."},"word_count":225,"has_tables":true,"body_markdown":"Item 5.03\n\nAmendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.\n\nOn June 15, 2026, the Company filed with the Secretary of State of the State of Delaware an amendment to its Amended and Restated Certificate of Incorporation to change the name of the Company from “Sensei Biotherapeutics, Inc.” to “Faeth Therapeutics, Inc.” (the “Name Change Amendment”). The Name Change Amendment became effective immediately upon filing.\n\n \n\nThe Board approved the Name Change Amendment pursuant to Section 242 of the General Corporation Law of the State of Delaware. Pursuant to Section 242 of the Delaware General Corporation Law, stockholder approval was not required to approve or effect the Name Change Amendment. The Name Change Amendment will not in any way affect the voting or other rights that accompany the Company’s common stock, par value $0.0001 per share (“Common Stock”), or the validity or transferability of the shares of Common Stock currently outstanding.\n\nThe Common Stock will continue to be quoted on The Nasdaq Capital Market, but beginning with the opening of trading on June 16, 2026, trading is expected to be under the new symbol “FTH” (the “Symbol Change”). There will be no change to the Common Stock’s CUSIP in connection with the Name Change Amendment.\n\nA copy of the Name Change Amendment is attached hereto as Exhibit 3.1 and incorporated herein by reference."}